Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma

• Published in: Scientific reports Vol. 8; no. 1; pp. 14269 - 11
• Main Authors: Andersen, Maria K., Rise, Kjersti, Giskeødegård, Guro F., Richardsen, Elin, Bertilsson, Helena, Størkersen, Øystein, Bathen, Tone F., Rye, Morten, Tessem, May-Britt
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.09.2018; Nature Publishing Group; Nature Research
• Subjects: 14/63; 140/131; 38/39; 38/61; 38/90; 631/337/572; 631/45/320; 631/67/327; 692/4025/1752; 692/4028/67/589/466; Cancer surgery; Clinical medical disciplines: 750; DNA microarrays; Extracellular matrix; Gene expression; Histopathology; Humanities and Social Sciences; Klinisk medisinske fag: 750; Magnetic resonance spectroscopy; Medical disciplines: 700; Medisinske Fag: 700; Metabolism; Metabolites; Metabolomics; multidisciplinary; Oncology: 762; Onkologi: 762; Prostate cancer; Prostatectomy; Science; Science (multidisciplinary); Stroma; Tumors; VDP; Biochemical Recurrence (BCR); Grade Group; High Resolution Magic Angle Spinning; Stromal Reaction; Prostate Cancer Tissue Samples
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-32549-1

Reactive stroma is a tissue feature commonly observed in the tumor microenvironment of prostate cancer and has previously been associated with more aggressive tumors. The aim of this study was to detect differentially expressed genes and metabolites according to reactive stroma content measured on the exact same prostate cancer tissue sample. Reactive stroma was evaluated using histopathology from 108 fresh frozen prostate cancer samples gathered from 43 patients after prostatectomy (Biobank1). A subset of the samples was analyzed both for metabolic (n = 85) and transcriptomic alterations (n = 78) using high resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS MRS) and RNA microarray, respectively. Recurrence-free survival was assessed in patients with clinical follow-up of minimum five years (n = 38) using biochemical recurrence (BCR) as endpoint. Multivariate metabolomics and gene expression analysis compared low (≤15%) against high reactive stroma content (≥16%). High reactive stroma content was associated with BCR in prostate cancer patients even when accounting for the influence of Grade Group (Cox hazard proportional analysis, p = 0.013). In samples with high reactive stroma content, metabolites and genes linked to immune functions and extracellular matrix (ECM) remodeling were significantly upregulated. Future validation of these findings is important to reveal novel biomarkers and drug targets connected to immune mechanisms and ECM in prostate cancer. The fact that high reactive stroma grading is connected to BCR adds further support for the clinical integration of this histopathological evaluation.